Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Exp Cell Res. 2013 Apr 3;319(10):1575–1585. doi: 10.1016/j.yexcr.2013.02.025

Fig. 5.

Fig. 5

Regression of SK-N-DZ and SK-N-BE2 tumors in nude mice after the treatments. Treatments: control (CTL, no treatment for 21 days), tumor bearing mice (7 days after tumor implantation) were injected at the tumor site with miR-138 mimic (50 μg DNA/injection/mouse), hTERT shRNA plasmid (50 μg DNA/injection/mouse) + APG (10 μg/injection/mouse), and miR-138 mimic (50 μg DNA/injection/mouse) + APG (10 μg/injection/mouse) on alternate days for 2 weeks. All animals were then sacrificed for analyzing the tumors. (A) Mice with SK-N-DZ and SK-N-BE2 xenografts. (B) Bar graphs for presenting regression of tumors. We used 6 animals per group. Difference between CTL group and a treatment group was considered significant at *p < 0.05 or **p < 0.01.

HHS Vulnerability Disclosure